Dan Vogl

31PUBLICATIONS
181CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Feb 06, 2026
The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target.

Zhiwei Ang, Annette Castro, Luca Paruzzo

|Jan 15, 2026
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy.

Matthew Ho, Luca Paruzzo, Julia Han Noll

|Aug 12, 2025
A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma.

Taxiarchis Kourelis, Sikander Ailawadhi, Dan T Vogl

|Apr 25, 2025
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma.

Sarah A Holstein, Shebli Atrash, Hira Mian

|Dec 27, 2024
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement.

Mahmoud R Gaballa, Omar Castaneda Puglianini, Adam Cohen

|Dec 04, 2024
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.

Dan T Vogl, Shebli Atrash, Sarah A Holstein

Pageof 6

Frequent Collaborators

15 joint publications

Adam D Cohen

12 joint publications

Alfred L Garfall

9 joint publications

Sandra Susanibar-Adaniya

5 joint publications

Marco Ruella